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EDV, ESP, SV, SW, and PVA and then compared to baseline. The results are in
Table 1.
Results: The TandemHeart device reduced the stroke work by 65% (p ¼0.013),
stroke volume by 77%, (p ¼0.020), and PVA reduction of 52% (p ¼0.061)
relative to Baseline. The Impella CP reduced the stroke work by 3% (p ¼0.758),
stroke volume by 11%, (p ¼0.42), and PVA by 23% (p ¼.391) relative to
Baseline.
Conclusions: Percutaneous ventricular assist for acute for myocardial injury affords
ventricular unloading during cardiac recovery. The Tandem heart device appears to
offer an advantage over the Impella based on these preliminary data that need to be
validated clinically.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/NeTCT-454
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Background: Direct Stenting (DS) has become a feasible and safe technique, with
potential clinical beneﬁts, but it is only performed in 30 to 60% of all PCIs. The aim of
this study is to evaluate the success of direct Svelte Acrobat Integrated Stent System
(ISS) via radial approach and 5 French Catheters. This unique system permits easy
delivery, deployment and post-dilatation of a cobaltchromium stent, designed to direct
stenting.
Methods: Patients with Coronary Artery Disease (CAD) were prospectively
enrolled at three centers in Sao Paolo, Brazil, to percutaneous Coronary Inter-
vention (PCI) with direct stenting via radial approach and 5 F catheters. The
Primary end point was the ISS success, deﬁned as direct stenting without post-
dilatation with additional balloon and ﬁnal stenosis less than 20% with TIMI III
ﬂow.
Results: Fifty patients with 55 lesions were included. Procedure success was 98%.
In two cases the device couldn’t cross the lesion and we had to predilate, so direct
stent success was 96%. Direct stenting without additional balloon post-dilatation
and residual stenosis less than 20% was sussessfull in ﬁfty lesions, so the ISS
success was 91%. The procedure length time was 21 minutes (SD¼9), the ﬂuo-
roscopy time was 437 seconds (SD¼ 280) and contrast volume used was 103 cm3
(SD¼33). Final residual stenosis, by QCA, was only 3.4% (SD¼4). Considering
the reduced need for additional catheters, there were 20% saving in procedure
costs. There were no bleeding or vascular complications. At eight months the
event-free survival was 84%.
Conclusions: Direct stenting with the Svelte Acrobat ISS is safe and efﬁcacy in
selected patients with CAD by radial approach and 5 French catheters and also
associated to potential procedure costs reduction.
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Tongxinluo reduces infarct size by promoting endothelial adhesion junction
integrity in reperfused diabetic hearts via PPAR-a pathway
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Background: Structural and functional disruption of microvascular barrier
caused by ischemia/reperfusion results in uncontrolled inﬂammation and
ischemia/reperfusion injury (IRI). Hyperglycemia may aggravate myocardial IRI
since it worsens the barrier function. Whether Tongxinluo (TXL) is involved in
reperfused diabetic heart protection through protecting cardiac microvascular
endothelial cells (CMECs) is unknown. In order to conﬁrm the effect and
mechanism of TXL-mediated cardiac protection, studies in vitro and in vivo
were conducted.
Methods: HCMECs were cultured in normal (5.5mM) and high glucose (18mM) for
48 h respectively followed by glucose-oxygen-serum deprivation (GOSD) for 2 h and
reoxygenation for 2 h. TXL (800mg/ml), PPAR-a inhibitor MK886 (1mM) were
supplemented. Endothelial monolayer permeability was assessed. VE-cadherin inter-
nalization was detected by confocal microscope and western blotting. ICAM-1
expression was detected by western blotting. ZDF rats with Type 2 diabetes mellitus
(T2DM) underwent 45 min ligation and 3 h reperfusion of LAD. Vascular perme-
ability and infarct size were determined by FITC-dextran and TTC staining
respectively.
Results: Endothelial monolayer permeability was signiﬁcantly increased after the
GOSD/ reoxygenation treatment in a time and glucose concentration-dependent
manner. Compared with the control group, TXL dramatically decreased the ﬂuores-
cence intensity (1925138 vs. 3558133) and ICAM-1 expression, but remarkably
increased the membrane/total VE-cadherin [(354)% vs. (846)%] in HCMECs.
TXL signiﬁcantly reduced ﬂuorescence intensity (2914388 vs. 4728483) and
infarct size [(456)% vs. (523)%] of ZDF rats with T2DM in AMI/reperfusion
model compared with control group. These protective effects of TXL were partly
inhibited by MK886.
Conclusions: Accordingly, TXL protects reperfused diabetic heart through
attenuating VE-cadherin-mediated paracellular hyperpermeability via PPAR-a
pathway.w Devices and Innovation B133
